IN THE CLAIMS:

- 1. (Currently amended) An isolated nucleic acid molecule comprising <u>SEQ ID NO: 1</u> any one of <u>SEQ ID NOs: 1, 4-5, 7, 9, 11 or 13</u>, or a fragment of any one of <u>SEQ ID NOs: 1, 4-5</u>, 7, 9, 11 or 13, wherein said fragment <u>nucleic acid molecule</u> encodes a polypeptide <u>that binds to OGF having at least one biological activity of an OGF receptor (OGFr)</u>.
 - 2. (Cancelled)
- 3. (Currently amended) An isolated nucleic acid molecule, the <u>full-length</u> complement sequence of which hybridizes under stringent conditions to <u>SEQ ID NO: 1</u> any one of <u>S</u>
- 4. (Withdrawn) An isolated nucleic acid molecule comprising an antisense sequence of any one of SEQ ID NOs: 1, 4-5, 7, 9, 11 or 13 SEQ ID NO:1.
- 5. (Currently amended) An expression vector comprising any one of the isolated nucleic acid molecules of Claims 1, 3-4 or 38[-39].
 - 6. (Original) A cell, transformed with the expression vector of Claim 5.
 - 7-13. (Cancelled)
- 14. (Currently amended) A pharmaceutical composition comprising the isolated nucleic acid molecule of any one of claims 1, 3 or 38[-39] and a pharmaceutically acceptable carrier.
- 15. (Withdrawn) A pharmaceutical composition comprising the isolated nucleic acid molecule of claim 4 and a pharmaceutically acceptable carrier.
- 16. (Currently amended) A pharmaceutical composition comprising the expression vector of claim 5 and a pharmaceutically acceptable carrier.

- 17. (Currently amended) A pharmaceutical composition comprising the cell of claim 6 and a pharmaceutically acceptable carrier.
 - 18-37. (Cancelled)
- 38. (Currently amended) An isolated nucleic acid molecule encoding a protein wherein said protein binds OGF and has comprises a the sequence as set forth in SEQ ID NO: 2 any one of SEQ ID NOS: 2, 6, 8, 10, 12 or 14.
 - 39. (Cancelled)